Endometrial stromal sarcoma is a rare cancer that starts in the connective tissue of the uterus. It most often affects adults, especially around or after midlife, and early symptoms of endometrial stromal sarcoma can include abnormal vaginal bleeding, pelvic pain, or a feeling of pressure in the lower belly. Some types grow slowly over years, while others are more aggressive, so the outlook can vary. Treatment for endometrial stromal sarcoma usually includes surgery, and some people also need hormone therapy, radiation therapy, or chemotherapy. It may help to know that doctors have studied this condition for decades, and survival depends a lot on the subtype, stage, and how far it has spread.
How many people live with Endometrial stromal sarcoma?
A reliable recent count of how many people are living with endometrial stromal sarcoma worldwide or in the United States is not available from a single trusted source. It is generally described as a very rare cancer of the uterus, but published global and U.S. totals are not consistent enough to give one firm number.
Overview
Endometrial stromal sarcomaSymptoms
Endometrial stromal sarcoma often causes unusual vaginal bleeding, especially after menopause or between periods. Many with endometrial stromal sarcoma also notice pelvic pain, pressure, or a growing belly. Early symptoms of endometrial stromal sarcoma can be mild.
Outlook and prognosis
Many living with endometrial stromal sarcoma do well for years, especially when it is found early and can be fully removed. Outlook depends mostly on the subtype, stage, and whether it comes back after treatment.
Causes and risk factors
Endometrial stromal sarcoma has no clear lifestyle cause. Risk may be higher with past pelvic radiation, long-term tamoxifen use, and certain hormone-related factors, while rare tumor-linked gene changes are usually acquired during life rather than inherited.
Genetic influences
Genetics can play a role in endometrial stromal sarcoma, but most cases are not clearly inherited. Many living with endometrial stromal sarcoma have tumor gene changes that help confirm the diagnosis and sometimes guide treatment decisions.
Diagnosis
Endometrial stromal sarcoma is usually suspected after abnormal uterine bleeding or pelvic pain. Ultrasound or MRI can show a uterine mass. Diagnosis is confirmed with a tissue sample, usually after surgery or biopsy.
Treatment and drugs
Treatment for endometrial stromal sarcoma often starts with surgery to remove the uterus, and sometimes the ovaries. Some people also need hormone therapy, especially for slow-growing disease. Radiation or chemotherapy may be used when it has spread or returned.
Symptoms
Unexpected bleeding between periods or after menopause is often what first stands out for people with Endometrial stromal sarcoma. Some also notice pelvic pain, pressure, or a slow increase in lower-belly fullness, while others have few clear signs at first. Symptoms vary from person to person and can change over time. Because the early symptoms of Endometrial stromal sarcoma can overlap with fibroids and other more common uterine problems, ongoing bleeding or pain should be checked.
Bleeding may be heavier than usual, happen between periods, or start again after menopause. For many people with Endometrial stromal sarcoma, this is the symptom that first disrupts daily life and leads to a medical visit.
Some people feel a dull ache, cramping, or pain low in the pelvis that does not match their usual cycle. It may be mild at first or become more noticeable with sex, exercise, or long periods of sitting.
A growing tumor can create pressure in the pelvis, with a sense of fullness or heaviness. Day to day, it can feel like sitting comfortably takes more effort or waistbands feel tighter around the lower abdomen.
Some may notice the lower belly looking more swollen or feeling firmer because the uterus is enlarging. This can be mistaken for bloating or weight gain, especially when it happens gradually.
How people usually first notice Endometrial stromal sarcoma?
Many people first notice endometrial stromal sarcoma because of unusual vaginal bleeding, especially bleeding between periods, after menopause, or periods that suddenly become heavier or last longer than usual. Some also develop pelvic pain, pressure, bloating, or a feeling of fullness in the lower belly, and a few notice the uterus seems enlarged or that they need to urinate more often because of pressure on nearby organs. These symptoms are more often caused by noncancerous conditions, but when bleeding patterns clearly change or pelvic symptoms do not go away, it is important to get checked.
Types of Endometrial stromal sarcoma
Endometrial stromal sarcoma can affect daily life in different ways depending on how fast the tumor grows. In practice, the main types of Endometrial stromal sarcoma are low-grade and high-grade, and they can differ in how quickly symptoms appear and how severe they feel. Symptoms don’t always look the same for everyone. Many people notice abnormal uterine bleeding, pelvic pain, or pressure, but faster-growing forms are more likely to cause symptoms that build quickly.
Low-grade ESS
This type usually grows more slowly, so symptoms may come on gradually over months or even longer. Many living with low-grade Endometrial stromal sarcoma notice abnormal bleeding, pelvic pressure, or cramping that can be mistaken for fibroids or heavy periods. Some also have no clear symptoms at first, and the tumor is found during imaging or surgery for another reason.
High-grade ESS
This type tends to grow and spread more quickly, so symptoms are often more intense or appear over a shorter time. People with high-grade Endometrial stromal sarcoma may have heavier bleeding, stronger pelvic pain, a rapidly enlarging pelvic mass, or symptoms linked to spread outside the uterus. Not everyone will experience every type, but high-grade disease is generally more likely to cause sudden changes in how someone feels.
Can I slow down the onset of symptoms?
No, there is no good evidence that lifestyle changes can meaningfully delay the start of symptoms in endometrial stromal sarcoma, a rare cancer of the uterus. Keeping a healthy weight and talking with your doctor about long-term hormone exposure, especially estrogen without progesterone or tamoxifen, may help lower risk for some people, but this is not the same as preventing the cancer and the evidence is limited because this disease is rare. There is no routine screening test or proven medicine to stop it from starting, but getting unusual vaginal bleeding, pelvic pain, or belly swelling checked early is still a smart and worthwhile step.
What genetics can tell you about symptoms
In endometrial stromal sarcoma, genetic changes are mainly useful for showing which subtype of the cancer is present, and that can give clues about how fast it may grow and how likely symptoms are to appear earlier or become more severe. For example, some gene changes are linked to slower-growing forms, while others are tied to more aggressive forms that may cause symptoms such as abnormal uterine bleeding, pelvic pain, or a growing pelvic mass sooner. Even so, genetics usually does not predict a unique set of day-to-day symptoms, and many people with different genetic changes can have similar early symptoms.
Causes and risk factors
In many people with endometrial stromal sarcoma, the exact cause is not clear, but it begins when cells in the uterine lining support tissue pick up DNA changes over time. Risk factors for endometrial stromal sarcoma may include older age, prior radiation treatment to the pelvis, and past use of tamoxifen, a drug used for some breast cancers. Some gene changes are found in the tumor itself, but these are usually not inherited, and family history is not a major risk factor for most people. Lifestyle factors such as body weight may affect hormone levels, but their role in endometrial stromal sarcoma is less certain than in more common endometrial cancers. Think of risk factors as pieces of a puzzle, not the whole picture.
What are the most common causes or risk factors?
The exact cause of endometrial stromal sarcoma is usually not known, but many living with it have gene changes that develop in the tumor cells over time rather than an inherited change passed down through the family. The most clearly linked risk factors are past radiation treatment to the pelvic area and long-term use of tamoxifen, a medicine used for some breast cancers. It is also seen most often in adults around midlife, often in the 40s or 50s, although it is still very rare.
Environmental and biological risk factors
The risk factors for endometrial stromal sarcoma are not as clear as they are for more common uterine cancers. Doctors often group risks into internal (biological) and external (environmental). Most people who develop endometrial stromal sarcoma do not have one single obvious cause, but a few patterns are seen more often.
Endometrial stromal sarcoma is most often found in adults in their 40s and 50s, although it can happen earlier or later. Age does not directly cause the cancer, but risk appears to rise through midlife.
Past radiation treatment to the pelvis can raise the chance of a later uterine sarcoma, including endometrial stromal sarcoma. When this happens, it usually appears years after the radiation exposure.
Long-term tamoxifen treatment for breast cancer has been linked with a higher risk of some uterine cancers, including uterine sarcomas. The overall risk is still low, but this medical history matters.
Endometrial stromal sarcoma often responds to hormones, especially estrogen. Long-term exposure to estrogen-based medicines may increase risk in some people, particularly if estrogen is used without progesterone in someone who still has a uterus.
Genetic risk factors
Most endometrial stromal sarcomas are linked to genetic changes that arise in the tumor cells themselves, not genes a parent passes on at birth. A common pattern is a gene fusion, where parts of two genes become joined and push cells to keep growing. Different subtypes of endometrial stromal sarcoma often have different genetic changes, which is why lab testing of the tumor is so important.
Chromosome swaps: Many cases begin with a chromosome rearrangement, meaning pieces of DNA break and rejoin in the wrong place. This can create a fused gene that sends abnormal growth signals in the uterine stromal cells.
Low-grade fusions: Low-grade endometrial stromal sarcoma often has gene fusions such as JAZF1-SUZ12 or related changes. These are found in the tumor, help confirm the diagnosis, and are not usually inherited.
High-grade changes: High-grade endometrial stromal sarcoma often has different changes, including YWHAE-NUTM2 fusions or BCOR-related alterations. These findings help explain why some tumors behave more aggressively and why subtype matters.
Inherited risk: For most people, there is no clearly established inherited gene change that strongly raises the risk of endometrial stromal sarcoma. Genetic risk factors for endometrial stromal sarcoma are usually changes inside the tumor rather than a family trait passed from parent to child.
Lifestyle risk factors
Some lifestyle-related factors may influence the risk of endometrial stromal sarcoma, although direct research is limited because this cancer is rare. The clearest links are through body weight, physical activity, and habits that affect hormone balance over time. When people ask about lifestyle risk factors for endometrial stromal sarcoma, it is most accurate to focus on patterns that may raise estrogen exposure or promote chronic inflammation.
Carrying excess body fat can increase estrogen production after menopause. Higher estrogen exposure may stimulate hormone-sensitive uterine tissues and could contribute to risk.
Regular physical activity helps with weight control, insulin sensitivity, and hormone regulation. Too little exercise may indirectly raise risk by promoting obesity and metabolic dysfunction.
A diet high in calorie-dense, highly processed foods can make weight gain and metabolic problems more likely. Over time, this may worsen hormonal and inflammatory pathways that can support cancer development.
Alcohol can affect estrogen levels and may contribute to weight gain. While evidence specific to endometrial stromal sarcoma is limited, heavier drinking may add to hormone-related cancer risk overall.
Risk prevention
With endometrial stromal sarcoma, there is no sure way to prevent the cancer completely because the exact cause is often not clear. For many, reducing risk means focusing on factors linked to estrogen exposure, using medicines carefully, and getting unusual bleeding checked early. Some prevention is universal, others are tailored to people with specific risks. Because endometrial stromal sarcoma is rare, these steps lower risk rather than guarantee prevention.
Abnormal uterine bleeding after menopause or between periods should be assessed promptly. Early evaluation can help detect endometrial stromal sarcoma sooner, even though it does not always prevent it from starting.
Long-term estrogen treatment without progesterone can raise the risk of some uterine cancers. If you use menopausal hormone therapy, ask your doctor which type and dose fit your situation best.
Tamoxifen can be very helpful for breast cancer treatment, but it may increase the risk of uterine cancer in some people. Anyone taking it should report new spotting, heavier periods, or pelvic pain without delay.
Staying in a healthy weight range may help lower estrogen levels after menopause. This can reduce risk for cancers of the uterine lining and may also matter for some people at risk of endometrial stromal sarcoma.
Can you prevent Endometrial stromal sarcoma?
No, there is no sure way to prevent endometrial stromal sarcoma, a rare cancer that starts in the support tissue of the uterus, because it often develops without a clear cause. Some things may raise risk, such as past radiation treatment to the pelvis or long-term use of certain hormone-related medicines, so it is worth reviewing these with your doctor, but most people who get this cancer could not have prevented it.
Transmission
If you or someone close to you has Endometrial stromal sarcoma, you do not need to worry about catching it through sex, kissing, shared food, blood contact, or everyday contact at home. Endometrial stromal sarcoma is a rare cancer of the uterus, and it is not infectious or contagious in any way.
People often ask about how Endometrial stromal sarcoma is inherited, but most cases are not passed from parent to child and happen by chance as cells in the uterus change over time. In some tumors, doctors find gene changes in the cancer cells themselves, but these are usually not the kind of changes that run in families.
When to test your genes
For endometrial stromal sarcoma, genetic testing is usually not used for early detection because there is no routine screening gene test. After diagnosis, testing the tumor can help confirm the subtype and guide treatment. Inherited gene testing may be worth discussing only if you have a strong family history of uterine or other cancers.
Diagnosis
Endometrial stromal sarcoma is usually diagnosed after symptoms such as unusual vaginal bleeding, pelvic pressure, or a mass seen on an exam or scan lead to further testing. Because these signs can overlap with more common conditions like fibroids, the diagnosis of endometrial stromal sarcoma often depends on tissue testing rather than symptoms alone. It’s natural to worry when symptoms don’t have a clear explanation.
A clinician may feel an enlarged uterus or notice other changes that suggest a growth in the pelvis. This exam cannot confirm endometrial stromal sarcoma, but it helps decide which tests are needed next.
Transvaginal or pelvic ultrasound is often one of the first imaging tests used to look for a uterine mass or thickening. It can show that something is abnormal, but it usually cannot tell for sure whether the growth is this specific cancer.
MRI gives a more detailed picture of the uterus and nearby tissues than ultrasound. It can help doctors judge the size of the tumor, how deeply it may extend, and whether features look more suspicious for sarcoma than for a benign fibroid.
CT of the abdomen, pelvis, or chest may be used when doctors need to check for spread beyond the uterus. This is more often part of staging after the cancer is suspected or confirmed.
How is Endometrial stromal sarcoma diagnosed?
Doctors usually suspect endometrial stromal sarcoma after symptoms like unusual vaginal bleeding or pelvic pain, or when a growth in the uterus is seen on an exam or imaging tests such as an ultrasound or MRI scan. The diagnosis is confirmed by removing a small piece of tissue, often during a biopsy or surgery, and checking it under a microscope. In some cases, extra lab tests on that tissue, including genetic tests, can help tell it apart from other uterine growths, but the main diagnosis comes from the tissue exam.
Stages of Endometrial stromal sarcoma
The stages of endometrial stromal sarcoma describe how far the cancer has grown or spread, which helps guide treatment and outlook. In many living with endometrial stromal sarcoma, staging is worked out after imaging, surgery, and lab testing of the tissue. Early and accurate diagnosis helps you plan ahead with confidence.
Stage I
The cancer is only in the uterus. This is the earliest of the stages of endometrial stromal sarcoma, although surgery is still usually needed to confirm exactly how far it has grown.
Stage II
The cancer has grown beyond the uterus but is still within the pelvis. It may involve nearby tissues such as the ovaries, fallopian tubes, or other pelvic structures.
Stage III
The cancer has spread farther within the abdomen or to nearby lymph nodes. For many, this means treatment may need to address both the main tumor and areas of spread.
Stage IV
The cancer has spread to the bladder or rectum, or to distant parts of the body such as the lungs. At this stage, symptoms can be more wide-ranging, and care often focuses on both controlling the cancer and easing day-to-day problems.
Outlook and prognosis
The outlook for endometrial stromal sarcoma depends mainly on the subtype and stage at diagnosis, with low-grade tumors often growing slowly and having a relatively favorable long-term prognosis, while high-grade disease behaves more aggressively and is more likely to recur or spread. For low-grade endometrial stromal sarcoma, many patients do well for years after surgery, but late recurrences can occur even after a long disease-free interval, so prolonged follow-up is important. High-grade endometrial stromal sarcoma and undifferentiated uterine sarcoma are associated with a substantially worse prognosis, with higher rates of metastasis and shorter survival. Survival is generally best when the cancer is confined to the uterus and completely removed, and worse when there is advanced-stage, recurrent, or metastatic disease. Mortality varies widely by subtype and stage, but deaths are much more common in high-grade or disseminated cases than in low-grade localized tumors. Hormone-sensitive low-grade tumors may respond to hormonal therapy, which can help control recurrent disease and improve long-term outcomes in some patients.
Long-term effects
For many living with endometrial stromal sarcoma, the long-term picture depends a lot on the tumor type, stage, and whether it comes back after treatment. Some people do very well for years, while others need ongoing care because this cancer can return long after the first treatment. Thinking about the long-term effects helps because they may come from both the cancer itself and treatments such as surgery, hormone therapy, chemotherapy, or radiation. In some people, early symptoms of endometrial stromal sarcoma can come back later as a sign of recurrence, including abnormal bleeding or pelvic pressure.
Endometrial stromal sarcoma can come back months or even many years after treatment, which is why long follow-up is often needed. Recurrence may happen in the pelvis, abdomen, or lungs, and it can sometimes cause few symptoms at first.
Treatment often includes removal of the uterus, and sometimes the ovaries, which means pregnancy is no longer possible afterward. If the ovaries are removed before natural menopause, hormone levels drop suddenly and long-term effects can be more noticeable.
Sudden menopause can lead to hot flashes, vaginal dryness, sleep disruption, and changes in sexual comfort. Over time, low estrogen may also affect bone strength and heart health.
Some people have long-term pelvic or lower abdominal discomfort, pressure, or scar-related pain after surgery or radiation. Bowel or bladder changes can also persist, such as urgency, frequency, constipation, or loose stools.
How is it to live with Endometrial stromal sarcoma?
Living with endometrial stromal sarcoma often means coping with more than the cancer itself: many people face ongoing fatigue, pelvic pain or pressure, unexpected vaginal bleeding, and the emotional strain of scans, surgery, and sometimes long-term hormone treatment or other therapies. Daily life can become less predictable, with work, exercise, sex, sleep, and family routines sometimes needing to bend around symptoms, recovery, and follow-up visits. The people around you are often affected too, as partners, relatives, and friends may take on caregiving, childcare, transportation, or emotional support, but clear communication and practical help can make that shared burden feel more manageable.
Treatment and drugs
Treatment for endometrial stromal sarcoma usually centers on surgery to remove the cancer, often including the uterus and sometimes the ovaries, because this cancer is often driven by hormones. Depending on the stage and whether it has spread or come back, doctors may also use hormone-blocking treatment, radiation, or less often chemotherapy. For many people, treatment begins with small daily steps, such as taking hormone medicine regularly and keeping up with follow-up visits and scans. Not every treatment works the same way for every person, and care can differ between slow-growing and more aggressive forms of endometrial stromal sarcoma. If you are looking into treatment options for endometrial stromal sarcoma, it helps to know that the best plan depends on the tumor type, stage, and your overall health.
Can you cure Endometrial stromal sarcoma?
Sometimes, yes—if endometrial stromal sarcoma is found early and fully removed with surgery, many people can be cured. If it has spread or comes back, a cure is less likely, but treatment such as surgery, hormone treatment, and sometimes radiation or chemotherapy can help control the cancer, slow it down, and ease symptoms.
Non-drug treatment
Living with endometrial stromal sarcoma often involves more than surgery, radiation, or hormone treatment alone. Non-drug care is used to support recovery, ease symptoms, and help with day-to-day life, from pain and fatigue to sexual health and emotional stress. For many, treatment begins not at the pharmacy, but with rehabilitation, counseling, nutrition support, and practical help at home. Not every approach works the same way, so care is usually tailored to your symptoms, treatment plan, and overall health.
Pelvic floor physical therapy can help with bladder leaks, pelvic pain, pain with sex, and tightness after treatment. It uses gentle exercises, breathing, stretching, and hands-on techniques to improve comfort and control.
Physical therapy can build strength, improve balance, and make it easier to walk, climb stairs, or return to daily routines after surgery. Many living with endometrial stromal sarcoma also benefit from graded activity to ease cancer-related fatigue.
Regular movement, such as walking, light strength work, or supervised exercise, can help energy, sleep, mood, and overall function. Structured programs, like cancer rehabilitation, can help if you are deconditioned or unsure how to restart safely.
A dietitian can help if treatment affects appetite, digestion, weight, or bowel habits. This can be especially useful during recovery from surgery or if early symptoms of endometrial stromal sarcoma and treatment have made eating harder.
Your genes may have an impact on how drugs work for you
For people living with endometrial stromal sarcoma, inherited gene differences can sometimes affect how the body breaks down cancer medicines, which may change how well a treatment works or how likely side effects are. This matters most with some chemotherapy and supportive medicines, where one person may clear a drug quickly while another may have more buildup and stronger side effects, such as unusually severe nausea, fatigue, or low blood counts. Even so, for this cancer, doctors usually base treatment more on the tumor’s hormone sensitivity and other tumor features than on routine inherited drug-response testing, so this kind of genetic testing is not a standard part of care for most people.
Pharmacological treatments
Drug treatment for endometrial stromal sarcoma depends a lot on the subtype and whether the cancer has spread or come back after surgery. Many living with endometrial stromal sarcoma are offered hormone-blocking medicines first when the tumor is the slower-growing, hormone-sensitive type, while chemotherapy is more often used for faster-growing disease. Not everyone responds to the same medication in the same way. In advanced or recurrent cases, treatment may be adjusted over time based on symptoms, scan results, and side effects.
Megestrol acetate and medroxyprogesterone are hormone medicines often used for low-grade endometrial stromal sarcoma. They work by reducing the hormone signals that can help these tumors grow. Common side effects can include weight gain, fluid retention, and a higher risk of blood clots.
Letrozole, anastrozole, and exemestane lower estrogen levels and are commonly used in hormone-sensitive disease. They are often chosen for recurrent endometrial stromal sarcoma or when long-term control is the goal. Joint aches, hot flashes, and bone thinning can happen over time.
Leuprolide or goserelin may be used to switch off estrogen production from the ovaries in people who have not gone through menopause. These drugs are sometimes combined with other hormone treatments. Side effects may feel similar to menopause, such as hot flashes, mood changes, or sleep trouble.
Doxorubicin, sometimes with ifosfamide, may be used when endometrial stromal sarcoma is high-grade, fast-growing, or no longer responding to hormone treatment. These medicines aim to slow cancer growth rather than target hormones. Side effects can include nausea, fatigue, low blood counts, and a risk of heart strain with higher total doses.
Genetic influences
In endometrial stromal sarcoma, genetics often matter most inside the tumor itself rather than through genes passed down in a family. It’s natural to ask whether family history plays a role. For many living with endometrial stromal sarcoma, the key gene changes are usually acquired over time in uterine cells, and some tumors have distinctive gene rearrangements that help doctors confirm the diagnosis and better understand how the cancer may behave.
That means genetic testing for endometrial stromal sarcoma is often done on the tumor tissue, not just through a blood or saliva test looking for inherited risk. Most people with endometrial stromal sarcoma do not have a clear inherited cause, although your care team may still ask about relatives with uterine, colon, or other cancers if the wider family history suggests a hereditary cancer syndrome. In day-to-day terms, this can affect which tests are ordered and how treatment and follow-up are planned.
Is Endometrial stromal sarcoma genetic?
Genetics can play a role in endometrial stromal sarcoma, but most cases are not clearly inherited. Many living with endometrial stromal sarcoma have tumor gene changes that help confirm the diagnosis and sometimes guide treatment decisions.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are widely found in the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, having a variant linked to a condition suggests a possible association rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some cases, though, a single well-characterized variant in a particular gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
In endometrial stromal sarcoma, treatment is often shaped by the gene changes found in the tumor itself, not just by where the cancer started. Tumor testing can help confirm the exact subtype, and that matters because lower-grade tumors often behave differently from higher-grade ones and may respond to different medicines. Many people living with endometrial stromal sarcoma also hear about hormone receptors; if the cancer cells use estrogen or progesterone signals to grow, medicines that lower or block these hormones can be helpful.
Genetics is only one factor, but these test results can give doctors a clearer idea of how genetics affect treatment for endometrial stromal sarcoma and whether standard therapy is likely to work well. Higher-grade tumors often have different genetic changes and may be less likely to respond to hormone therapy, so chemotherapy or another drug approach may be considered instead. Inherited gene differences that affect how your body handles cancer drugs are not a routine part of care for this cancer, but tumor genetic testing is becoming more important for treatment planning and sometimes for finding a clinical trial.
Interactions with other conditions
Endometrial stromal sarcoma can be harder to recognize because its symptoms often overlap with more common conditions such as fibroids, endometriosis, or adenomyosis. Many living with endometrial stromal sarcoma notice abnormal bleeding, pelvic pressure, or pain that can look a lot like these noncancerous problems, which may delay diagnosis. Doctors call it a comorbidity when two conditions occur together, and that can make symptoms harder to sort out. Endometrial stromal sarcoma is also often sensitive to hormones, so other hormone-related conditions and past or current use of hormone treatments may affect care decisions. If the cancer has spread, it may cause problems in places such as the lungs, which can overlap with breathing symptoms from common lung diseases. Because treatment often involves surgery and sometimes hormone-blocking medicines, other health issues such as blood clotting disorders, heart disease, or bone thinning can also matter when choosing the safest plan.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Endometrial stromal sarcoma?
Other conditions that can look similar to endometrial stromal sarcoma include common noncancerous problems such as fibroids, uterine polyps, and adenomyosis, which is when tissue from the lining of the womb grows into the muscle wall. Doctors also need to rule out other cancers of the uterus, especially cancer of the lining of the womb and a rare cancer of the uterine muscle, because they can cause similar signs like abnormal bleeding, pelvic pain, or a growing pelvic mass.
History
For much of medical history, endometrial stromal sarcoma was not easy to recognize. Many living with this cancer would have had symptoms that seemed similar to more common problems, such as unusual vaginal bleeding, pelvic pressure, or pain, so early cases were often grouped together with other uterine tumors rather than identified as a distinct disease.
As doctors began examining uterine tissue more closely under the microscope in the late 19th and early 20th centuries, they noticed that some rare tumors looked different from the more common cancers of the womb. Early reports called them by several names, and the way the condition was classified changed more than once as specialists tried to sort out which growths behaved slowly and which were more aggressive. This mattered in real life: two people with what seemed like the same diagnosis on paper could have very different experiences over time.
By the mid-to-late 20th century, pathologists had a clearer picture of endometrial stromal sarcoma as a cancer arising from the supportive tissue of the uterine lining rather than from the lining cells themselves. That helped doctors separate it from leiomyosarcoma and other uterine sarcomas, which can look similar at first but do not always act the same way. As medical science evolved, newer laboratory methods improved diagnosis and made it easier to understand why some tumors return years after treatment while others behave more aggressively from the start.
In recent decades, awareness has grown, and researchers have refined the categories used for these tumors. What used to be placed under one broad label is now divided more carefully based on how the cells look and how the tumor tends to behave. This has helped guide treatment decisions and follow-up, especially because early symptoms of endometrial stromal sarcoma can still overlap with benign conditions like fibroids or with other uterine cancers.
Today, the history of endometrial stromal sarcoma shows how medicine often moves step by step: from symptoms, to tissue patterns, to more accurate testing. Researchers later identified a genetic basis in many cases, but the main advance for patients has been better recognition, clearer diagnosis, and a more realistic understanding of prognosis. For many, this means care can be tailored more closely than it was in the past.